Get started
Novartis AGNovartis AGNovartis AG

Novartis AG

No trades
OverviewFinancialsNewsCommunityTechnicalsForecastsSeasonalsBondsETFs

Chart


Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪248.99 B‬ EUR
Dividend yield (indicated)
3.08%
Price to earnings Ratio (TTM)
20.00
Basic EPS (TTM)
6.44 EUR
Net income (FY)
‪12.47 B‬ EUR
Revenue (FY)
‪48.64 B‬ EUR
Shares float
‪1.69 B‬
Beta (1Y)
1.06

Employees


Employees (FY)
‪75.27 K‬
Change (1Y)
−616 −0.81%
Revenue / Employee (1Y)
‪646.21 K‬ EUR
Net income / Employee (1Y)
‪165.71 K‬ EUR

About Novartis AG


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Vasant Narasimhan
Website
novartis.com
Headquarters
Basel
Founded
1996
IPO date
May 7, 2001
Identifiers
2
ISIN CH0012005267
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Check out other big names from the same industry as NOT.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


N
NVS6224266
Novartis Capital Corp. 5.3% 05-NOV-2055
Yield to maturity
5.48%
Maturity date
Nov 5, 2055
N
NVS5894401
Novartis Capital Corp. 4.7% 18-SEP-2054
Yield to maturity
5.45%
Maturity date
Sep 18, 2054
US66989HAS7
Novartis Capital Corp. 2.75% 14-AUG-2050
Yield to maturity
5.43%
Maturity date
Aug 14, 2050
N
NVS6224265
Novartis Capital Corp. 5.2% 05-NOV-2045
Yield to maturity
5.37%
Maturity date
Nov 5, 2045
N
US66989HAH1
Novartis Capital Corp. 4.4% 06-MAY-2044
Yield to maturity
5.36%
Maturity date
May 6, 2044
N
XPND
Novartis Capital Corp. 4.0% 20-NOV-2045
Yield to maturity
5.36%
Maturity date
Nov 20, 2045
N
NVS3904288
Novartis Capital Corp. 3.7% 21-SEP-2042
Yield to maturity
5.28%
Maturity date
Sep 21, 2042
N
NVS6224264
Novartis Capital Corp. 4.6% 05-NOV-2035
Yield to maturity
4.67%
Maturity date
Nov 5, 2035
N
NVS5894400
Novartis Capital Corp. 4.2% 18-SEP-2034
Yield to maturity
4.49%
Maturity date
Sep 18, 2034
N
NVS6224263
Novartis Capital Corp. 4.3% 05-NOV-2032
Yield to maturity
4.32%
Maturity date
Nov 5, 2032
N
NVS6224251
Novartis Capital Corp. 4.1% 05-NOV-2030
Yield to maturity
4.09%
Maturity date
Nov 5, 2030

See all NOT bonds 

ETFs holding the stock


VXUS
Vanguard Total International Stock ETF
Weight
0.66%
Market value
‪3.86 B‬
USD
VEA
Vanguard FTSE Developed Markets ETF
Weight
0.92%
Market value
‪2.50 B‬
USD
IEFA
iShares Core MSCI EAFE ETF
Weight
1.16%
Market value
‪2.04 B‬
USD
CHDVD
iShares Swiss Dividend ETF (CH)
Weight
15.80%
Market value
‪1.35 B‬
USD
EFA
iShares MSCI EAFE ETF
Weight
1.36%
Market value
‪1.03 B‬
USD
CHSPI
iShares Core SPI(R) ETF (CH)
Weight
12.96%
Market value
‪877.87 M‬
USD
SMICHA
UBS ETF (CH) - SMI ETF -CHF dis-
Weight
17.16%
Market value
‪733.80 M‬
USD
SMIA
UBS ETF (CH) - SMI ETF Units -CHF acc-
Weight
17.16%
Market value
‪733.80 M‬
USD
VGK
Vanguard FTSE Europe ETF
Weight
1.75%
Market value
‪654.73 M‬
USD
SCHF
Schwab International Equity ETF
Weight
1.07%
Market value
‪628.27 M‬
USD
CHEURD.EUR
UBS ETF SICAV - UBS ETF - MSCI Switzerland 20/35 UCITS ETF -(hedged to EUR) A-dis- Distribution
Weight
14.08%
Market value
‪579.31 M‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of NOT is 131.24 EUR — it has increased by 0.97% in the past 24 hours. Watch Novartis AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on XETR exchange Novartis AG stocks are traded under the ticker NOT.
NOT stock has risen by 5.08% compared to the previous week, the month change is a 8.30% rise, over the last year Novartis AG has showed a 63.99% increase.
We've gathered analysts' opinions on Novartis AG future price: according to them, NOT price has a max estimate of 148.58 EUR and a min estimate of 92.97 EUR. Watch NOT chart and read a more detailed Novartis AG stock forecast: see what analysts think of Novartis AG and suggest that you do with its stocks.
NOT reached its all-time high on Feb 2, 2026 with the price of 127.70 EUR, and its all-time low was 26.42 EUR and was reached on Mar 4, 2009. View more price dynamics on NOT chart.
See other stocks reaching their highest and lowest prices.
NOT stock is 2.15% volatile and has beta coefficient of 1.06. Track Novartis AG stock price on the chart and check out the list of the most volatile stocks — is Novartis AG there?
Today Novartis AG has the market capitalization of ‪249.63 B‬, it has decreased by −0.28% over the last week.
Yes, you can track Novartis AG financials in yearly and quarterly reports right on TradingView.
Novartis AG is going to release the next earnings report on Apr 28, 2026. Keep track of upcoming events with our Earnings Calendar.
NOT earnings for the last quarter are 1.73 EUR per share, whereas the estimation was 1.69 EUR resulting in a 2.09% surprise. The estimated earnings for the next quarter are 1.82 EUR per share. See more details about Novartis AG earnings.
Novartis AG revenue for the last quarter amounts to ‪11.35 B‬ EUR, despite the estimated figure of ‪11.68 B‬ EUR. In the next quarter, revenue is expected to reach ‪11.58 B‬ EUR.
NOT net income for the last quarter is ‪2.07 B‬ EUR, while the quarter before that showed ‪3.36 B‬ EUR of net income which accounts for −38.52% change. Track more Novartis AG financial stats to get the full picture.
Yes, NOT dividends are paid annually. The last dividend per share was 3.63 EUR. As of today, Dividend Yield (TTM)% is 2.92%. Tracking Novartis AG dividends might help you take more informed decisions.
Novartis AG dividend yield was 3.38% in 2025, and payout ratio reached 61.77%. The year before the numbers were 3.95% and 67.17% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Feb 9, 2026, the company has ‪75.27 K‬ employees. See our rating of the largest employees — is Novartis AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Novartis AG EBITDA is ‪19.77 B‬ EUR, and current EBITDA margin is 40.92%. See more stats in Novartis AG financial statements.
Like other stocks, NOT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Novartis AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Novartis AG technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Novartis AG stock shows the strong buy signal. See more of Novartis AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.